These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2778470)

  • 21. Postmarketing surveillance of new drugs: I. Review of objectives and methodology.
    Wardell WM; Tsianco MC; Anavekar SN; Davis HT
    J Clin Pharmacol; 1979; 19(2-3):85-94. PubMed ID: 370159
    [No Abstract]   [Full Text] [Related]  

  • 22. Restrictions on clinical research.
    Eur J Clin Pharmacol; 1974 Oct; 7(6):479. PubMed ID: 4439873
    [No Abstract]   [Full Text] [Related]  

  • 23. Toward Better-Quality Compounded Drugs - An Update from the FDA.
    Woodcock J; Dohm J
    N Engl J Med; 2017 Dec; 377(26):2509-2512. PubMed ID: 29281577
    [No Abstract]   [Full Text] [Related]  

  • 24. Present attitudes of governmental drug regulatory agencies.
    Noel PR
    Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283
    [No Abstract]   [Full Text] [Related]  

  • 25. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 26. Assessing Drug Safety in Children - The Role of Real-World Data.
    McMahon AW; Dal Pan G
    N Engl J Med; 2018 Jun; 378(23):2155-2157. PubMed ID: 29874532
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA weighs communicating drug-related risk to patients.
    Stephenson J
    JAMA; 1999 Aug; 282(6):515. PubMed ID: 10450699
    [No Abstract]   [Full Text] [Related]  

  • 28. Review of the processes for FDA oversight of drugs, medical devices, and combination products.
    Sweet BV; Schwemm AK; Parsons DM
    J Manag Care Pharm; 2011; 17(1):40-50. PubMed ID: 21204589
    [No Abstract]   [Full Text] [Related]  

  • 29. New drugs-miracles or mirages?
    JAMA; 2014 Jan 22-29; 311(4):423. PubMed ID: 24449329
    [No Abstract]   [Full Text] [Related]  

  • 30. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM; Shin J; Guglielmo BJ
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract]   [Full Text] [Related]  

  • 31. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 32. Addressing Pharmaceutical Injuries: The US Landscape.
    Bakker C; Honig N
    Clin Pharmacol Ther; 2018 Mar; 103(3):384-385. PubMed ID: 28850676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primum non nocere.
    Gifford RW
    JAMA; 1977 Aug; 238(7):589-90. PubMed ID: 577959
    [No Abstract]   [Full Text] [Related]  

  • 34. Can postmarketing surveillance help to effect optimal drug therapy?
    Strom BL; Melmon KL
    JAMA; 1979 Nov; 242(22):2420-2. PubMed ID: 385922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Legal problems in psychiatric drug prescription.
    Appleton WS
    Am J Psychiatry; 1968 Jan; 124(7):877-82. PubMed ID: 5688683
    [No Abstract]   [Full Text] [Related]  

  • 36. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
    Greene JA; Watkins ES
    N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
    [No Abstract]   [Full Text] [Related]  

  • 37. Nonprescription drugs: an overview.
    Hodes B
    Int J Health Serv; 1974; 4(1):125-30. PubMed ID: 4829892
    [No Abstract]   [Full Text] [Related]  

  • 38. Key Elements in Adverse Drug Reactions Safety Signals: Application of Legal Strategies.
    Chen B; Restaino J; Tippett E
    Cancer Treat Res; 2019; 171():47-59. PubMed ID: 30552656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The assessment of adverse drug reactions in clinical trials.
    Petrie WM; Levine J
    Int Pharmacopsychiatry; 1978; 13(4):209-16. PubMed ID: 730486
    [No Abstract]   [Full Text] [Related]  

  • 40. CONTROL OF DRUG TOXICITY IN THE UNITED STATES OF AMERICA.
    WESTON JK; WESTON K
    Practitioner; 1965 Jan; 194():16-21. PubMed ID: 14259685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.